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Abstract
Molecular beacons (MBs) are dual-labeled oligonucleotides that fluoresce only in the presence of 
complementary mRNA. The use of MBs to target specific mRNAs allows sorting of specific cells 
from a mixed cell population. In contrast to existing approaches that are limited by available 
surface markers or selectable metabolic characteristics, the MB-based method enables the 
isolation of a wide variety of cells. For example, the ability to purify specific cell types derived 
from pluripotent stem cells (PSCs) is important for basic research and therapeutics. In addition to 
providing a general protocol for MB design, validation and nucleofection into cells, we describe 
how to isolate a specific cell population from differentiating PSCs. Using this protocol, we have 
successfully isolated cardiomyocytes differentiated from mouse or human PSCs with ~97% purity 
as confirmed using electrophysiology and immunocytochemistry. After designing MBs, their 
ordering and validation requires two weeks, and the isolation process requires three hours.
INTRODUCTION
The ability to separate different cell types is important for a wide range of biological and 
medical studies, including the quantification of cells with specific phonotypes for disease 
diagnosis, the isolation of terminally differentiated induced pluripotent stem cells (iPSCs) at 
different stages of maturation, and the selection of cells from a mixed cell population that 
possess unique characteristics or functions. In most cases, the selection and separation 
methods rely on cell physical properties (e.g. size, shape, stiffness, etc.), cell surface protein 
expression, or genetic modifications. In particular, cells derived from pluripotent stem cells 
(PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells 
(iPSCs) 1,2, are becoming a powerful tool that dramatically changes how pharmaceuticals 
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are developed and validated for therapies by allowing patient-specific mechanistic studies, 
and personalized drug testing for efficacy and toxicology. For example, researchers have 
used cells derived from PSCs to model genetic diseases such as long QT syndrome 1 
(LQT1) 34. PSC-based disease modeling is challenging, however, since many disorders 
affect only specific, terminally differentiated, cell populations. Currently available PSC 
differentiation systems typically generate mixed populations containing undifferentiated 
cells or undesirable cells which could cause teratoma formation or interfere with high 
throughput quantification5. Thus, purification of tightly controlled populations of terminally 
differentiated cells derived from PSCs is desirable to prevent detrimental effects.
Methods developed to isolate specific populations of differentiated cells derived from 
PSCs
Various techniques have been developed to isolate specific cell types from differentiating 
PSCs including positive selection6,7, negative selection8, genetic modification9,10, or 
metabolic negative selection11,12. The most popular method for isolating specific 
populations of cells is to use antibodies to target surface proteins6,7. However, the lack of 
specific cell surface proteins that can be targeted by conventional antibody-based 
fluorescence-activated cell sorting (FACS) remains one of the major challenges commonly 
encountered when isolating terminally differentiated cells from differentiating PSCs. Several 
methods that do not require specific antibodies are available, including the classic 
purification technique that relies on a fluorescent reporter gene driven by a promoter such as 
NKX2.5, ISL1 or MHC in genetically modified cell lines 6,7. However, such reporter-gene 
based methods may not be applicable to certain PSCs such as iPSCs where selecting a line 
with the reporter gene (such as GFP) integrated at a single, correct genomic location is very 
challenging. Alternatively, non-genetic approaches such as the use of a Percoll gradient13 or 
the use of cell metabolism12,14 have been developed. While these methods are useful in 
specific applications, they are limited to targeting specific cellular phenotypes which may be 
dynamic during the differentiation process6. Together, these methods may lack the required 
detection specificity due to their not using a specific molecular marker highly expressed in 
target cell types. To address the limitations of the above approaches, we developed a method 
to isolate specific cell types by directly targeting intracellular mRNAs using molecular 
beacons (MBs) and sorting via FACS.
Development of the protocol
MBs are dual-labeled oligonucleotides ~15–30 bases long with a fluorophore on one end 
and a quencher molecule on the other end (Figure 1A) 15. Since their development in 
1996 15, MBs have been used to identify specific mRNA or DNA sequences in 
solution 16,17, and to visualize the intracellular localization of mRNA transcripts in 
individual living cells 18,19. MBs excel in both types of applications because they fluoresce 
only when hybridized to complementary oligonucleotides, a property that confers molecular 
specificity and target versatility. In the absence of oligonucleotide target, MBs assume a 
hairpin conformation that brings the fluorophore and quencher moieties into contact, 
resulting in significant quenching of the fluorophore and very low background fluorescence 
(Figure 1A). Hybridization of the MB with target oligonucleotide sequence opens the 
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hairpin, thus physically separating the fluorophore from the quencher, restoring fluorescence 
upon excitation (Figure 1B).
It was demonstrated in proof of concept studies that MBs could be used in a flow cytometry 
assay to identify cells expressing a specific mRNA in a mixed cell population without 
affecting the expression of this mRNA 20. We have recently developed a MB based method 
for the isolation of cardiomyocytes (CMs) from a differentiating culture of PSCs by 
targeting highly expressed specific mRNAs21,22. Specifically, we designed and validated 
MBs targeting cardiac troponin T (cTNT or TNNI3) or myosin heavy chain genes (α/βMHC 
or MYH6/7) mRNAs respectively that are highly expressed only in CMs. MBs were then 
delivered into differentiating mouse or human PSCs using nucleofection followed by FACS 
sorting of CMs based on MB signal. Control studies confirmed that CM specific MBs had 
low background signal in all non-CM cells in the differentiating culture of PSCs, confirming 
detection specificity. We found that 97% of mouse or human cells isolated using FACS 
based on MB signal demonstrated CM-like characteristics in assays including 
electrophysiology, flow cytometry, and immunocytochemistry. This approach, using a 
FACS sorter to purify CMs based on MB signal from specific mRNA expression, is very 
versatile and can be adopted for the isolation of other cell types from differentiating PSCs. 
Although the later steps of the procedure (step 18 onwards) uses the isolation of CMs from 
differentiating human PSCs as an example application, this part of the protocol can be 
readily modified to isolate other specific cell types providing MBs have been successfully 
designed to target genes highly expressed in the cell type of interest.
Experimental Design
There are five essential elements of the MB-based protocol for the isolation of a specific cell 
type from differentiating cells (Figure 2): (1) identification of specific mRNAs that are 
highly expressed only in the desired cell type (Figure 2A); (2) design and validation of MBs 
targeting specific mRNAs with high signal-to-background ratio (Figure 2B); (3) delivery of 
MBs into a mixed population of cells, for example from differentiating PSCs, with high 
efficiency (Figure 2C); (4) isolation of cells with FACS based on MB signal (Figure 2D); 
and (5) validation of cell characteristics (Figure 2E). Although the experimental design 
described here uses the isolation of CMs as an example, the MB based method can be 
readily modified for the isolation and enrichment of other cell types by designing MBs to 
target the specific gene(s) highly expressed in the particular cell type, as described in the 
procedure below.
Identification of specific mRNAs highly expressed in target cells
In order to use MBs to isolate specific cells from a mixed cell population, target mRNAs 
that are highly and uniquely expressed in the cell type of interest must be identified. These 
mRNAs need to have a relatively high abundance so that, when MBs are hybridized to their 
mRNA target in the specific cells (such as CMs), the resulting fluorescence signal is at least 
5-fold higher than that in other cell types. Genes encoding structural proteins have been used 
by several groups in the past21,23. However, for isolating novel cell types the gene 
expression profile must be quantified using qRT-PCR (or DNA microarray) to identify 
specific mRNAs that have high levels of expression (>10 fold) compared with that in other 
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cell types in the in the PSC differentiation culture (Figure 2a). It may be necessary to choose 
multiple target genes highly expressed in the cell type of interest so that at least one mRNA 
will be specific enough and result in high MB signal. This also raises the possibility of using 
multiple MBs to target a specific subpopulation, such as ventricular CMs rather than all 
CMs.
MBs can be designed to target human genes, mouse genes, or in some cases both. An MB 
can be designed for both human and mouse genes only when the selected target sequence is 
identical for mouse and human genes. Specifically, MBs targeting the MYH6/7 or TNNT2 
mRNA described in this protocol were designed for both mouse and human genes, allowing 
the use of HL-1 CMs (a mouse cell line) for characterization of CM-specific MBs. If an MB 
is designed for applications with human cells, but the MB targeting sequence does not have 
a perfect match in the mouse gene, a separate positive control cell line consisting of a 
standard control cell (e.g., 293 or 3T3 cells) transfected with a plasmid to highly express the 
target human gene should be used for MB validation. If an MB is designed only for isolating 
CMs from mouse cells, using HL-1 CMs as a positive control is sufficient.
Design and validation of MBs targeting specific mRNAs—Once specific genes are 
identified, MBs can be designed by targeting regions of the corresponding mRNA where 
excellent probe accessibility and signal specificity can be achieved. The target sequences of 
a specific mRNA may not be accessible due to secondary structure of the mRNA or RNA-
binding proteins. To enhance target accessibility, an RNA secondary structure prediction 
program (e.g., mFOLD) can be used to identify potential single stranded regions of the 
mRNA (Figure 1D). It is also important to select target sequences with a sufficient (35% – 
65%) GC content so that MBs so designed will have a good affinity to their targets. Finally, 
the NCBI BLAST search is typically performed to identify unique sequences of the mRNA 
for MBs to target (target sequences), and to minimize the number of sequences that differ 
from a target sequence by only a few (< 5) bases. Steps 1–10 identify and use three 
oligonucleotide sequences, the target sequence, a MB with its loop and stem sequences, and 
a mismatched (mutant) sequence. The target sequence in the specific mRNA needs to be 
carefully selected to ensure MB signal specificity. The MB loop sequence is complementary 
to the target sequence, and the MB stem sequence is typically 5 nucleotides long with high 
GC content. The MB is formed by selecting a dye-quencher pair and conjugating the dye 
and quencher to the 5′ and 3′ ends of the MB sequence respectively. The most affordable 
options are the FAM fluorophore with Black Hole Quencher 1 or the Cy3 fluorophore with 
Black Hole Quencher 2. The use of Cy3 dye is recommended for experiments where another 
molecule is taking up the FITC/GFP wavelengths, or there is significant autofluorescence. 
For labs without an oligonucleotide synthesizer facility, it is recommended to order MBs 
from one of the many high quality oligonucleotide providers such as IDT and MWG 
Operon, where HPLC purification of the MBs to eliminate the free dye is performed. A 
mismatched sequence, typically contains 4–6 mutations compared to the target sequence, is 
used to test the quality of MB synthesis in vitro. Since it is impossible to accurately predict 
target accessibility in living cells, multiple (three to five) MBs are usually designed and 
tested against a specific mRNA.
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The most important issue with the MB based approach is signal specificity. Ideally, MBs 
delivered into a mixed cell population exhibit a high level of signal only in target cells but 
not in other cell types due to the high expression of the gene in target cells. However, in 
certain cases, a high level of non-specific signal from MBs may occur due to the delivery 
method (such as microinjection), MB degradation, or MB-protein interactions in cells. To 
determine MB signal specificity, a negative control random MB was designed whose loop 
sequence was generated using ‘random walk’ and does not match with any mRNA sequence 
in the genome of interest. Any signal from the random MBs after delivery into the target 
cells or positive control cells (cells highly express the target gene, such as the Hl-1 cells for 
CM isolation) will be non-specific background signal. The ratio of MB signal from specific 
mRNA to the background signal from random MB gives the signal-to-background ratio, 
S/N. To have high signal specificity, the MB designed should have a S/N > 5 in target cells.
In addition to using a random MB as a negative control, two assays can be performed to 
further confirm signal specificity. The first is to use a mutant MB that has 4–5 bases 
mismatch with the target sequence (Figure 1C). After delivery into the positive control cells 
(e.g. HL-1 cells), such a mutant MB should only generate a low background signal. The 
second assay is to down-regulate the expression level of the target mRNA using RNA 
interference (siRNA) in the positive control cells or to up-regulate the expression level using 
a plasmid in a cell type unrelated to the target cells, such as mouse embryonic fibroblasts 
(MEF) for CM isolation. High MB specificity is ensured if the MB signal decreases after 
down-regulation and increases after up-regulation of the target gene. Plasmid expression in a 
control cell type (such as MEF) is a reliable method, but is less ideal compared with the 
siRNA approach, since the MB accessibility might be different from that encountered when 
the gene is expressed endogenously. Note that the same MB design may have different 
target accessibilities in human and mouse cells.
Delivery of MBs into a mixed population of cells with high efficiency and 
throughput—Uniform, rapid delivery of MBs into all cell types in the differentiating 
culture of PSCs is important. In order for MBs to increase their fluorescence intensity by 5–
10 fold upon hybridizing to their complementary mRNA targets, cells need to take up a 
sufficient number (usually > 2,000) of MBs per transfection. This is based on the estimate 
that the ideal number of mRNA transcripts per cell is ≥200 for effective isolation using 
FACS. The large MB/mRNA ratio is to ensure that most (if not all) mRNA targets in a cell 
are hybridized by MBs.
There are several MB delivery methods, including the use of microinjection, cell penetrating 
peptides (CPPs), streptolysin O (SLO), and electroporation 24. Microinjection is low-
throughput, and often interferes with normal cell function. Although the CPP- or SLO-based 
delivery of MBs could have high efficiency and throughput, the delivery efficiency is 
typically cell type dependent and may not work for the mixed cell population resulting from 
PSC differentiation. In addition CPP or SLO based delivery of MBs might lead to 
endosomal entrapment and degradation, causing a high level of background signal. 
Electroporation has been used to deliver oligonucleotides into living cells, but conventional 
methods may result in low cell viability. Recent advances in electroporation technology 
(such as nucleofection) have led to a reduction in the harmful events, including heat 
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generation, metal ion dissolution, pH variation, and oxide formation. The advanced 
electroporation methods lead to cellular internalization of oligonucleotide probes with high 
transfection efficiency (>90%) and high cell viability (>80%)22. Using nucleofection, it is 
possible to uniformly deliver MBs into millions of cells within 20 min. Because MBs must 
be delivered into cells quickly, due to the inherently short functional lifespan of exogenous 
nucleic acid sequences in a cellular environment25, we recommend delivery via 
nucleofection. It is also important to isolate cells based on the MB signal within 4 hours to 
avoid potential artifact caused by MB degradation. MBs may be re-introduced into cells at 
later time points if necessary, and several groups have shown that the MB signal from each 
delivery becomes undetectable after 24 hours26. Small numbers of MBs may enter the cell 
nucleus; however the resulting fluorescence signal should be low since no target mRNA is 
present in the nucleus and the probability of random genomic integration of MBs is 
negligible 19,20,24,27,28.
It is also important to ensure that the difference in MB signal between target cells and other 
cell types is not an artifact due to preferential uptake of MBs by a specific cell type. It is 
therefore important to determine whether or not all cells in the mixed population take up 
MBs uniformly (Figure 2C). To this end, the random sequence MB is modified to have two 
identical fluorophores instead of a dye-quencher pair (Figure 1C) and used as a delivery 
control probe for delivery studies. After probe delivery into differentiating cells, 
fluorescence signals are quantified and a relatively uniform signal distribution is expected. 
This experiment is designed to confirm that the MB signal specificity is due to MB 
hybridization to target mRNAs rather than MBs preferentially entering one cell type but not 
others.
Isolation of target cells with FACS based on MB signal—FACS sorting is currently 
the only method that can selectively isolate a specific cell population at a rate of millions of 
cells per hour based on fluorescence. Since MBs can detect cells that express various levels 
of target mRNAs, the flow cytometry assay may not generate very distinct populations of 
cells if there is a large variation of target mRNA expression levels in the differentiating 
PSCs to which MBs are delivered. It is therefore critical to design MBs that target 
abundantly expressed mRNAs in cells of interest in order to isolate them with high 
specificity and throughput. It is also important to fine-tune the FACS parameters so that 
cells with low levels of fluorescence signal will not be isolated. In addition, the FACS 
output streams should be carefully analyzed for the effect of sorting on both the cell viability 
and cell yield. Cell viability can be assessed by plating the MB positive population and 
measuring cell death over a 2-day period after sorting. To assess the yield of the FACS 
based target cell isolation, cell populations with high MB signal (MB positive) and low MB 
signal (MB negative) are collected after the sorting experiment, and both populations are 
compared using qRT-PCR and functional assays. A significant difference in target cell 
characteristics (such as specific gene expression) between the MB negative and MB positive 
populations may be used as an indication to confirm that MB based sorting has a high 
specificity.
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Target cell characterization using qRT-PCR and immunocytochemistry—To 
ensure that a high purity target cell population is isolated from differentiating PSCs, MB 
positive cells must be tested to ascertain that (i) they highly express the specific gene(s) and 
(ii) they have low (or zero) expression levels of genes associated with other cell lineages. 
For example, to isolate CMs, specific markers such as TNNT2, TNNI3, MYH6/7 and MYL2 
can be analyzed in the MB positive population using both qRT-PCR and 
immunocytochemistry to yield population-based results as well as quantitative information 
on the number of cells expressing specific markers. It is also necessary to demonstrate that 
the MB positive cells do not express genes that are markers of other cell types, including 
skeletal muscle, neural progenitor cells, fibroblasts and endothelial cells. To ensure that the 
MB positive cells represent a high purity population of target cells, a high percentage of 
cells expressing specific markers and a low percentage of cells expressing markers 
indicating other cell lineages are required.
Applications
The MB based method presents a novel approach for cell isolation due to its versatility and 
the ability to target intracellular mRNAs. A major hurdle to the current use of cells 
differentiated from hPSCs for many applications is the potential tumorigenicity or aberrant 
tissue formation after cell transplantation. Since many types of cells do not have specific 
surface protein markers for isolation and it is still impractical to genetically modify hiPSCs 
to express a selection marker, the MB based method may offer a useful means of purifying 
specific cells such as CMs generated from PSCs. The MB based method is applicable to the 
isolation of any cell type that expresses specific gene marker(s) to which corresponding 
MBs can be designed and validated. No surface protein marker for isolation is required. For 
example, MBs can be designed to target specific genes that are highly expressed only within 
neuronal or pancreatic beta cells, so the MB based method can be used to isolate neurons or 
beta cells generated from PSCs with high purity. MBs could also be used as a tool to 
evaluate cell differentiation protocols to provide rapid feedback on the yield and efficiency 
of the process.
In addition to isolating specific cells from the mixed cell population of differentiating PSCs, 
the MB based approach can also be applied to the isolation and enrichment of pure cell 
populations after transdifferentiation, in which one mature somatic cell type is transformed 
into another mature somatic cell type without undergoing a pluripotent state or using a 
progenitor cell type as an intermediate step. Another potential application of the MB based 
method described in this protocol is to isolate gene-modified cells after precise genome 
editing using TALENs and CRISPR/Cas systems. The modification of an endogenous gene 
is often in the form of single-base mutation (or correction of single-base mutation), deletion 
or insertion, making selection of gene-modified cells very challenging. With the addition of 
few wobble mutations in the target gene, MBs could be designed to target the site of 
modification in the corresponding mRNA, and the gene-modified cells can be isolated using 
the method described here.
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MATERIALS
REAGENTS
CRITICAL: The materials listed here are those needed for the example application of 
isolating cardiomyocytes from hPSC. For different applications some materials will need to 
be substituted, for example, antibodies and cell culture media.
• Cell line used for target cell purification. We have used human pluripotent stem 
cell lines, e.g., H1 (WISC Bank), BJ1 (a gift from George Daley at Harvard 
university) and
• Suitable control cell lines. For the example application described here, we use 
HL-1 CMs (a gift from William Claycomb at Louisiana State University) and 
mouse embryonic fibroblasts (MEF) (CF-1) cells (ATCC, SCRC-1040)
CRITICAL: Other control cells can also be used. Prepare cells that highly express the MB 
target gene(s) for validation. For example, HL-1 CMs can be used as a positive control for 
testing CM-specific MBs. For negative control, various types of non-CM cells such as 
fibroblasts, or smooth muscle cells or endothelial cells can be used.
• DMEM/F-12 (Life Tech, cat. no. 11320-033) - CM Specific
• DMEM (Life Technologies, cat. no. 11965-092)
• Claycomb medium (Sigma cat. no. 51800C-500ML) - CM Specific
• Opti-MEM 1, no phenol red (Life Tech, cat. no. 11058-021)
• KnockOut serum replacement (Life Technologies, cat. no. 10828-028) - CM 
Specific
• FBS (ATCC, cat. no. 30-2020)
• PBS (Sigma-Aldrich, cat. no. D8537)
• Delivery Control MB (MWG, Sequence: 
ACGACGCGACAAGCGCACCGATACGTCGT, FAM dye added to both 5′ and 
3′ end, HPLC purification)
• Negative Control MB (MWG, Sequence: 
ACGACGCGACAAGCGCACCGATACGTCGT, Cy3 dye added to 5′ end and 
Black Hole Quencher 2 added to 3′ end, HPLC purification)
• Activin A (R&D Systems, cat. no. 338-AC-050) (Step #) - CM Specific
• BMP4 (R&D Systems, cat. no. 314-BP-010) (Step 12C only) - CM Specific
• bFGF (Life Technologies, cat. no. 13256-029) (Step 12C only) - CM Specific
• β-Mercaptoethanol (Sigma, cat. no. M7522) - CM Specific
• GlutaMAX (Life Technologies, cat. no. 35050-061)
• Antibiotic-Antimycotic (Life Technologies, cat. no. 15240-062)
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• Nonessential amino acid solution (NEAA;, Life Technologies cat. no. 11140-076) - 
CM Specific
• mTeSR1 (STEMCELL Technologies, cat. no. 05857)
• Matrigel (BD Biosciences, cat. no. 354277)
• Y27632 (Tocris, cat. no. 1254) - CM Specific
• Isoproterenol (Sigma, cat. no. I6504) - CM Specific
• Cell Line Nucleofector Kit V (Lonza, cat. no. VACA-1003)
• Trypsin-EDTA, 0.25% (wt/vol) (Life Tech, cat. no. 25200-056)
• Accutase (Life Tech, cat. no. A1110501)
• RNAEasy Miniprep Kit (Qiagen, cat. no. 74134)
• iScript cDNA Synthesis kit (Biorad, cat. no. 170-8891)
• iTaq™ Universal SYBR® Green Supermix (Biorad, cat. no. 172-5122)
• Paraformaldehyde 4% (wt/vol) in PBS (Santa Cruz Biotechnology, cat. no. 
30525-89-4)
Caution: Paraformaldehyde is harmful; avoid exposure.
• Triton X-100 (Sigma-Aldrich, cat. no. X100-500ML)
• Bovine Serum Albumin (Sigma-Aldrich, cat. no. A9576)
• Tween-20 (Sigma-Aldrich, cat. no. P9416)
• Anti-ACTN2 (Sigma-Aldrich, cat. no. SAB4503474-100UG) - CM Specific
• Anti-TNNT2 (Thermo Scientific, cat. no. MA5-12960) - CM Specific
• Mouse anti-cTnT (Thermo, cat. no. MS-295-P0) - CM Specific
• Anti-cTnI (Abcam, cat. no. ab10231) - CM Specific
• Goat anti-mouse IgG-Alexa Fluor 594 (Life Tech, cat. no. A-11001)
• Goat anti-rabbit IgG-Alexa Fluor 488 (Life Tech, cat. no. A-11005)
• DAPI (Sigma-Aldrich, cat. no. D8417-5MG)
• Cy3 goat anti-mouse (Jackson, cat. no. 115-166-003)
• Saponin (Sigma, cat. no. 47036-50G-F)
• PBS (Sigma, cat. no. D8537)
• Nuclease Free Tris-EDTA buffer, pH 7.0 or 8.0 (Life Tech, cat. no. AM9850G or 
AM9855G)
• T-75 flasks (Fisher Scientific)
• Liquid nitrogen
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• Ethanol, 70% (vol/vol)
• Milli-Q water
• Borosilicate glass (World Precision Instruments, Inc., cat. no. PG52151-4) - CM 
Specific
EQUIPMENT
• Real-Time PCR Machine (Life Tech, 7500 Fast or equivalent system)
• Benchtop centrifuge (e.g., Eppendorf 5415R or equivalent system)
• Plate Reader (Tecan, Safire or equivalent system)
• Laminar flow hood (Labconco or equivalent system)
• Lab-Tek eight-well chambered cover glass (Thermo Scientific, 155411 or similar 
cultureware)
• Cell culture multiwall plates, 6 wells and 12 wells (Greiner Bio-One, 657160 and 
665102 or simuilar cultureware)
• Centrifuge (e.g., Beckman Coulter Avanti J-30I or equivalent system)
• Liquid aspirator setup
• Nucleofector™ 2b Device (Lonza)
• Flow Cytometer (e.g., Accuri C6, BD or equivalent system)
• Flow Activated Cell Sorter (e.g., FACSaria III, BD or equivalent system)
• 0.22-μm filter (Nalgene or equivalent system)
• Inverted Fluorescence Microscope (e.g., Zeiss Axiovision or equivalent system)
• P-87 Flaming/Brown puller (Sutter Instrument Company, Novato, CA or equivalent 
system) - CM Specific
• EPC 7 amplifier (List Medical, Darmstadt, Germany or equivalent system) - CM 
Specific
• Origin 6.0 software (Microcal Inc., Northampton, MA or equivalent software) - 
CM Specific
REAGENT SETUP
Oligonucleotide Solutions—Resuspend oligonucleotides (MBs, target and mutant 
oligonucleotides designed in steps 1–10) in a nuclease free buffer to 100 μM at the 
recommended pH (either 7.0 or 8.0 depending on additional molecules). Make several 10 μL 
aliquots and freeze at −20 °C to maximize their performance and stability (stored for up to 6 
months).
Cytokine Culture Media—Add BMP4, Activin A, and FGF2 to DMEM/F12 cell culture 
media to achieve final concentrations of 10 ng/ml, 3 ng/ml and 5 ng/ml respectively.
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END-2 Conditioned Culture Media—Add DMEM/F12 media to confluent mouse 
endodermal cell line END-2 cells for 1 day. Remove and sterile filter the media.
Nucleofector Solution—The nucleofector solution kit contains two liquids, the solution 
and the supplement. Store them separately at 4°C where they are stable for 12–18 months 
according to manufacturer’s specifications. Once the supplement is added to the solution it 
is stable for 2 weeks in our hands.
Action Potential Measurement Tips- (CM Specific)—Fabricate glass 
microelectrodes from borosilicate glass and pull using a P-87 Flaming/Brown puller or 
equivalent system. The tip resistance of the microelectrode should be 40–80 MΩ when filled 
with a 3 mol/L KCl solution.
EQUIPMENT SETUP
EPC 7 amplifier (or equivalent system, CM Specific)—Adjust the junction potential 
between the microelectrode solution and the bath solution to zero and compensate for the 
microelectrodes’ capacitance. Filter and digitize signals at 10 kHz.
PROCEDURE
Cell-specific-MB Design
Timing- 10 days
Step 1: Identify genes highly expressed in target cells based on literature search, 
experience, and/or prior results. For example, for isolating CMs, cardiac troponin T 
(cTNT) and α/β myosin heavy chain (MYH6/7) were chosen. Check if the genes 
identified are also highly expressed in other cell types in the mixed cell population 
during PSC differentiation; high mRNA expression in other cell types could lead to an 
inability to separate target cells from mixed cell population.
Step 2: Confirmation of high gene expression levels using RT-PCR. Prepare total 
RNA from at least 100,000 cells from the specific cell population using the RNeasy 
mini plus kit according to the manufacturer’s instructions.
Step 3: Convert the RNA into cDNA using the iScript cDNA synthesis kit from BioRad 
or equivalent system.
Step 4: Perform either Taqman or SYBR Green real-time PCR for each sample in 
multiplexed reactions performed in triplicate using a 7500 Fast Real-Time PCR system 
or equivalent. Run all annealing steps at 60°C.
Step 5: Normalize all target genes to GAPDH. Calculate differences in CT values (ΔCT 
= CT gene of interest − CT GAPDH in experimental samples) for each target mRNA by 
subtracting the mean value of GAPDH (relative expression = 2−ΔCT). Proceed with the 
mRNA for which the highest ratios between the target gene and GAPDH were obtained.
Step 6: Prediction of the secondary structure of the target mRNA. Enter the 
sequence into a secondary structure prediction program (e.g., mFOLD) to predict single 
stranded regions in the target mRNA.
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Step 7: Designing the MB loop region. Identify a sequence of 15–30 bases of the 
target mRNA predicted to be single stranded. Select a region with 35% – 65% GC 
content, and design a complementary sequence with a predicted melting temperature 
(Tm) of 60°C in 150 mM NaCl when hybridizes to the target mRNA (the prediction of 
melting temperature Tm could be performed using the online tool ‘HyTher’, available at 
http://ozone2.chem.wayne.edu/Hyther/hythermenu.html). This sequence (the reverse 
complement of the mRNA target sequence) will form the loop of the MB and ensure the 
MBs will be able to hybridize to the target sequence.
TROUBLESHOOTING
If the positive control cells are from a different species than that of target cells, MBs should 
be designed to target mRNA sequences that are identical in both species (such as mouse and 
human). If the target sequence in the gene of interest is not identical for both species, 
positive control cells should be generated to highly express the target gene by transfecting a 
cell line unrelated to the target cells with a plasmid encoding the target gene.
Step 8: Add a stem to the loop sequence by appending complementary arms of five 
bases long to the 3′ and 5′ end of the loop sequence respectively. MBs with a total 
length of more than 40 bases may form a secondary structure therefore should be 
avoided. It may be desirable to add only one arm with a 5-base sequence 
complementary to the loop sequence on the opposing end in order to create a shorter 
MB (shared-stem MB). A 5-base stem with a GC content of ~60% should be strong 
enough to generate a stem-loop hairpin structure with a Tm of ~50°C, which can be 
determined using the online tool ‘DNA mfold’ (available at http://www.bioinfo.rpi.edu/
applications/mfold/old/dna/).
Critical Step: Do not use Guanine for the first three bases at the 5′ end due to its 
tendency to quench fluorophores.
TROUBLESHOOTING
Step 9: Use the NCBI BLAST search tool to identify other mRNAs that the MB may 
hybridize to in the cell type of interest. To do this, use the MB sequence as input. The 
closest match should be the target mRNA sequence identified in Step 7, and the second 
closest match should have a mismatch of at least four base pairs compared with the 
mRNA target sequence.
Step 10: Design a mismatched target sequence. Using the results of the NCBI 
BLAST search from Step 9, the second closest sequence could be used as the 
“mismatched sequence” if it contains 4–6 bases not complementary to the beacon loop 
sequence. If the second closest sequence from the BLAST search has more than 6 bases 
not complementary to the beacon loop sequence, design a new “mismatched sequence” 
by mutating 4 randomly selected bases in the target sequence..
Step 11: To form the MB, select a dye-quencher pair (as discussed in the Experimental 
Design section) and conjugate the dye and quencher to the 5′ and 3′ ends of the MB 
sequence respectively. To reduce background signal, attach the quencher to 3′ end to 
ensure that all MBs will have a quencher even if the fluorophore is not conjugated to the 
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MB due to a synthesis error. To determine MB performance, the synthetic target 
oligonucleotide (usually single strand DNA) with the same sequence as target mRNA, 
and mutant (mismatched) oligonucleotide should also be obtained for MB 
characterization in solution. Usually MBs with DNA backbones are sufficient for cell 
isolation. It may be necessary to design and test several (three to five) target-cell 
specific MBs which can be ordered simultaneously to reduce wait times.
TROUBLESHOOTING
Step 12: Re-suspend all oligonucleotides in nuclease free, 0.1x TE, pH 7.0 buffer at 100 
uM to make stock solutions.
Critical: Avoid freeze-thaw cycles to preserve stability and function of MBs.
Pause point: MB can be stored at −20°C or −80°C for up to 6 months after synthesis.
MB Validation in Solution
Timing- 2 hours
Step 13: Use a buffer mimicking cytosolic conditions (139 mM K, 12 mM Na, 4 mM 
Cl, etc) and make a 500 μL aliquot of 1 μM cell-specific MBs. Use the same buffer in 
separate tubes to dilute the target oligonucleotide and mismatched oligonucleotide to 
1.5 μM concentration. Make serial dilutions of the target and mismatched 
oligonucleotides respectively to establish dose dependence.
TROUBLESHOOTING
Step 14: Add 25 μL of MB solution to each well of a 384-well black-bottomed plate, 
then add 25 μL of each concentration of the solutions containing target oligonucleotide 
or mismatched oligonucleotide to their designated wells. Include one blank well and 
one well with DNAse 1 as negative and positive controls, respectively. Incubate at 37°C 
for 5 minutes to allow the solutions to equilibrate.
Step 15: Analyzing the fluorescence intensity of MBs using a microplate reader. 
Use a microplate reader to determine the fluorescence intensity of each well. From this 
establish a dose dependence curve using the serial dilutions of the target 
oligonucleotide. The MB signal at the highest target oligonucleotide concentration 
should generally be between 5 and 30 times higher than the background signal 
quantified in the negative control experiment in which the signal level of MBs without 
any target is measured. The MB signal in the well with the highest concentration of 
mismatched oligonucleotide should be no more than 1.5 times the background signal. 
Candidate MBs that do not meet these conditions should be disregarded due to lack of 
specificity and low S/N. Select MBs that satisfy these conditions for further testing.
TROUBLESHOOTING
MB delivery testing with cells
Timing- 1 day—Critical: Nucleofection is an electroporation method for transferring 
nucleic acids such as DNA and RNA molecules into cells. Under typical nucleofection 
conditions, most MBs are delivered into cell cytoplasm, with a small amount of MBs in the 
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cell nucleus. Since the target mRNAs are only in the cell cytoplasm, MBs delivered into the 
cell nucleus should not hybridize to any target nor result in specific fluoresce signal.
Step 16: Plate cells for delivery test (e.g., mouse embryonic fibroblasts) at 50–60% 
confluency in DMEM medium containing 10% vol/vol FBS and culture them overnight 
at 37°C.
Step 17: Add the delivery control MB (see Reagents section) to nucleofection solution 
to obtain a MB concentration of 500 nM.
Critical Step: To check the efficiency of MB delivery via nucleofection and select 
optimal delivery conditions, a delivery control MB (Figure 1C) is designed which has a 
non-specific, ‘random’ sequence with two FAM dyes conjugated to both 5′ and 3′ ends, 
allowing the probe to fluoresce without any target when delivered into living cells using 
nucleofection.
Step 18: Detach and suspend one million cells (from Step 16) per condition, wash with 
PBS.
Step 19: Centrifuge the cells at 90g for 10 minutes. The centrifugation should be gentle 
to avoid damaging the cells. Remove the supernatant, allowing cell pellet to remain 
undisturbed.
Critical Step: Ensure that all PBS is removed from the solution to avoid diluting the 
electroporation solution.
Step 20: Resuspend the cell pellet in the nucleofection solution that contains delivery 
control MBs (from Step 17).
Step 21: After MB delivery, gently centrifuge the cells at 90g for 10 minutes then 
aspirate the media. Resuspend the cells in PBS and analyze the cells using any standard 
flow cytometer to determine MB delivery efficiency. For flow cytometry assays, first 
run an untransfected sample. Use this non-fluorescent sample to set the lower limits of 
gates that can be used to detect MB positive cells.
TROUBLESHOOTING
Step 22: Optimization of nucleofection parameters. Perform nucleofection using a 
variety of programs to identify the optimal program with the highest uniform delivery 
efficiency. Changes in the electroporation program do affect cell viability, so great care 
must be taken to choose a program that does not kill a large number of cells. 
Immediately after nucleofection, gently pipette cells from the cuvette into cell culture 
medium and keep them there for at least 10 minutes.
MB specificity testing in positive and negative control cells respectively
Timing- 1 day
Step 23: Delivery of cell-specific MBs into positive control cells using nucleofection. 
Use the optimized nucleofection parameters and the procedure described in Steps 16–21 
to deliver the cell-specific MBs designed in Steps 1–11 and tested in Steps 13–15 into 
positive control cells (e.g., HL-1 cells for CM isolation)
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Step 24. Delivery of negative control MBs to positive control cells. Repeat Step 23 to 
deliver the negative control MB (see Reagents section) into a separate aliquot of 
positive control cells. As a further negative control, deliver the mutant negative control 
MB (Figure 1D) into a separate aliquot of positive control cells, as described in Step 23.
Step 25: Delivery of cell-specific MBs into other cell types using nucleofection. 
Deliver the cell-specific MBs into any other cell types you are using as controls (for 
example, smooth muscle cells, aortic endothelial cells and cardiac fibroblasts typically 
present in the differentiating PSCs). Use the optimized nucleofection parameters and the 
procedure described in Steps 16–22
Step 26: Analyze all cells after MB delivery using flow cytometry. After MB 
delivery, incubate cells for 10 min at 37°C, gently centrifuge the cells at 90g for 10 
minutes, and then aspirate the media. Resuspend the cells in PBS and analyze the cells 
using any standard flow cytometer. Use negative control cells to set the gates as in Step 
21.
Critical: This step should result in a strong fluorescent signal from cell-specific MBs in 
positive control cells (Step 23); low (typically ≤3%) fluorescence signal from the 
negative control (mutant) MBs (Step 24) (Figure 3C, 3D); and low false positive signal 
resulting from non-specific opening of the random MBs in other cell types (Step 25) 
(Figure 3B).
Critical Step: The flow cytometry analysis must be performed within 2 hours of MB 
delivery into the cells. Several groups have shown that non-specific MB signal may 
increase quickly ~2 hours after MB delivery due to MB degradation, resulting in a high 
level of false positives in flow cytometry analysis.
TROUBLESHOOTING
Step 27: Selection of the final cell-specific MBs. Repeat Steps 23–26 to select the 
final MB designs which result in high fluoresce signal in positive control cells (such as 
HL-1) and very low background fluoresce signal in negative control cells (such as non-
CM cells). These MBs will be used for further study for the isolation of target cells. In 
most of the cases, one cell-specific MB that has satisfactory performance (high positive 
signal and low background signal) will be sufficient.
Stem Cell Differentiation
Critical: Any differentiation protocol may be used for the selection/enrichment of cell type 
of interest. The following steps represent the method used for the isolation of CMs as an 
example. Alternatively, prepare CMs differentiated from hPSCs using any of the previously 
validated protocols 5,29–31
Timing- ~2–3 weeks
Step 28: Culture undifferentiated hPSCs on either mitotically inactivated MEF (STO) 
cells in DMEM/F12 supplemented with 20% serum replacement, 1% L-glutamine, 1% 
nonessential amino acids, 100 mM β-mercaptoethanol, and 4ng/ml basic fibroblast 
growth factor or feeder free culture systems 32. Change the medium every day and 
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transfer hPSCs to new feeder cells every 5 to 7 days. Culture cells for at least one 
passage after thaw before beginning differentiation.
Step 29: Coating of plates with Matrigel. Add 3 mL Matrigel solution to each 10 cm 
petri dish. Warm for at least 1 hour at room temperature (21–23 °C), then aspirate liquid 
just before use.
Step 30: Dissociation of hPSCs from feeder cell culture. When colonies are 80% 
confluent, remove hPSC culture medium and rinse with DMEM/F-12 medium. Add 3 
mL Dispase (1 mg/ml) to hPSC culture and incubate for about 20 min at 37 °C to 
dissociate them into small clusters (10–20 cells). There may be some batch to batch 
variation for dissociation time thus frequent microscopic examination ensures 
successful dissociation especially after 15 min from the addition with Dispase. Once 
dissociation is completed, add 7ml of DMEM/F12 medium to cell suspension and 
transfer to a conical tube. Centrifuge the cell suspension at 300 g for 5 minutes to 
harvest the cells. Repeat this procedure twice to make sure that Dispase is completely 
removed,
Step 31: Start of 2D hPSC differentiation. Resuspend cells in mTeSR 1 media and 
transfer cells onto Matrigel-coated plates from Step 29. Culture the cells for 24–48 hrs 
in mTeSR® media to allow them to expand.
Step 32: Induction of mesodermal differentiation. Replace media with cytokine 
media and incubate cells for 2 days.
Step 33: Remove the cytokine media and add END-2 conditioned media, incubate cells 
for 4 days.
Step 34: Supplementation with Isoproterenol to produce mature CMs. If desired, 
remove conditioned media and incubate cells with mTeSR® media containing 
isoproterenol (10 μM), a β–adrenergic receptor agonist, for at least 4 days to generate 
spontaneously beating CMs.
Deliver MBs into differentiating hPSCs for the isolation of target cells
Timing- 6 hours
Step 35: Gentle dissociation of intact differentiated cells using Accutase. Rinse one 
million cells from Steps 28–34 with PBS, then incubate them for 20 minutes with 2 ml 
Accutase at 37°C.
Step 36: Add 6 ml DMEM/F12 containing 10% vol/vol FBS to neutralize the Accutase 
before centrifuging cells at 90g for 10 minutes and aspirating the supernatant.
Step 37: Resuspend cells in nucleofection solution containing 500 nM of delivery 
control MBs.
Step 38: Use the optimal nucleofection program identified to deliver MBs into the 
mixed cell population. Immediately after nucleofection, gently pipette cells from the 
cuvette into the DMEM/F12 medium containing 10% vol/vol FBS and incubate cells for 
30 minutes at 37°C.
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Step 39: Analysis of signal from delivery control MB in cells using a flow 
cytometer. Gently centrifuge the cells at 90g for 10 minutes, then aspirate the media. 
Resuspend the pellet (cells) in PBS and analyze the cells using any standard flow 
cytometer. Cells in the mixed cell population should show uniform, high fluorescence 
signal. Use negative control cells to set the gates in flow cytometry assay as in Step 22.
TROUBLESHOOTING
Step 40: Delivery of cell-specific MBs into differentiating hPSCs using 
nucleofection. Detach one million cells from differentiating hPSCs generated from 
Steps 28–34 using the procedure described in Steps 35–36 and resuspend the cells in the 
nucleofection solution containing 500 nM of cell-specific MBs. Use the optimal 
nucleofection program identified to deliver MBs into the mixed cell population. Use a 
gentle centrifugation of 90g for 10 minutes to avoid damaging the cells. Immediately 
after nucleofection, gently pipette cells from the cuvette into at least 1 mL of 
DMEM/F12 medium containing 10% vol/vol FBS and incubate the cells for 10 minutes 
at 37°C.
Step 41: Analysis of cells using a flow cytometer. Gently centrifuge the cells at 90g 
for 10 minutes then aspirate the media. Resuspend the cells in PBS and analyze the cells 
using any standard flow cytometer. Use negative control cells to set the gates in flow 
cytometry assay as in Step 21.
TROUBLESHOOTING
Step 42: Sorting of cells using FACS. Gently centrifuge the cells at 90g for 10 
minutes, then aspirate the media. Resuspend in PBS and sort the MB positive cells 
using a cell sorter such as the FACS Aria II or a Jazz system. Use slightly more 
stringent gating conditions than that in the previous analysis (Step 41) to ensure high 
purity of isolated target cells. Gating strategies can be altered to provide the desired 
purity level by using more stringent conditions. Plate cells on appropriate dishes (MEA 
plates, 6 well dishes, etc) in the DMEM/F12 media containing 10% vol/vol FBS and 
incubate for 24–48 hours for subsequent target cell characterization assays.
Characterize target cells purified with cell-specific MBs
Timing- 2 days
Step 43: Characterize cells as appropriate for your particular experiment. Different 
assays may be used to confirm the function of the cell type of interest. We use the 
following to confirm the functionality of MB-sorted CMs and provide them here as an 
example. Option A describes how to characterize cells via RT-PCR. Option B describes 
how to characterize cells via immunocytochemistry. Option C describes how to 
characterize MB-sorted cells by intracellular flow cytometry based on the expression of 
protein markers. Option D describes how to measure action potential in purified CMs. 
Other functional assays, such as that for glucose sensitivity in insulin producing cells or 
P450 activity in hepatocytes may be appropriate in place of option D depending on the 
type of cells being isolated.
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Option A: RT-PCR of MB-sorted cells
i. Prepare total RNA with the RNeasy mini plus kit according to the manufacturer’s 
instructions from at least 100,000 cells from the previous step.
ii. Convert the RNA into cDNA using the iScript cDNA synthesis kit from BioRad.
iii. Perform either Taqman or SYBR Green real-time PCR using a 7500 Fast Real-
Time PCR system. Run all annealing steps at 60°C.
iv. Normalize all target genes to GAPDH in multiplexed reactions performed in 
triplicate. Calculate differences in CT values (ΔCT = CT gene of interest − CT 
GAPDH in experimental samples) for each target mRNA by subtracting the mean 
value of GAPDH (relative expression = 2−ΔCT). It is recommended to test at least 
three genes from each potential lineage (e.g., CM, fibroblast, neurons etc. for 
isolating CMs). The specific group of genes may vary depending on the MB target 
gene.
Option B: Immunocytochemistry of MB-sorted cells
i. Rinse the MB positive cells with PBS then fix them using 4% paraformaldehyde 
for 10 min at room temperature (21–23 °C).
ii. Wash cells twice with PBS and permeabilize them with 0.1 or 0.5% Triton X-100 
in PBS for 10 min.
iii. Block with 1% BSA in PBS for 60 min at room temperature and then incubate cells 
with antibodies specific for the protein marker of the target cell at 4°C overnight 
for immunostaining. For example, for MB-sorted CMs, one may use anti-ACTN2 
(1:100), mouse anti-TNNT2 (1:100), or rabbit anti-cTnI (1:100).
iv. Wash the cells three times with 1% Tween 20 in PBS and incubate with anti-mouse 
IgG– Alexa Fluor 594 (1:1000) or anti-rabbit IgG–Alexa Fluor 488 (1:1000) in 
PBS for 1 h at room temperature.
v. Counterstain the nuclei with DAPI (300 nM).
vi. Visualize the samples using a fluorescence microscope or confocal laser-scanning 
microscope.
Critical Step: MB fluorescence should be reduced to background levels 24 hours 
after delivery into the cells thus should not interfere with immunocytochemistry.
Option C: Characterization of MB-sorted cells by intracellular flow cytometry based on the 
expression of protein marker
i. Rinse the MB positive cells with PBS, incubate them with 2 ml Trypsin at 37°C for 
5 minutes.
ii. Wash the MB positive cells three times with PBS and centrifuge at 600g for 5 min 
at room temperature.
iii. Fix the cells with 2% (wt/vol) PFA for 20 min at room temperature.
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iv. Wash the cells two times with PBS and centrifuge at 600g for 5 min at room 
temperature.
v. Gently resuspend the cell pellets to the permeabilization buffer containing 5% (vol/
vol) FBS and 0.5% (vol/vol) saponin, and incubate for 20 min for permeabilization.
vi. Prepare the primary antibodies at appropriate concentrations in staining buffer with 
0.2% saponin, For MB-sorted CMs, the protein marker used is cTnT, but the 
following steps are valid for many other protein markers also. If using cTnT, use 
mouse anti-cTnT, in staining buffer with 0.2% saponin, and add them in the tube 
with a final antibody dilution of 1:100 for cTnT. Incubate overnight at 4°C.
vii. Wash the cells three times with staining buffer and centrifuge at 600g for 5 min at 
room temperature.
viii. Resuspend the cell pellets in staining buffer with saponin with a 1:200 dilution of 
secondary antibody, Cy3 goat anti-mouse (Jackson). Incubate the suspensions for 1 
hr min at room temperature.
Critical Step: Maintain the samples in the dark by covering them with aluminum 
foil after the addition of secondary antibody.
ix. Wash the cells three times with staining buffer and centrifuge at 600g for 5 min at 
room temperature.
x. Resuspend the cells in 100 μl of PBS with 2% (vol/vol) FBS and quantify cTnT 
positive cells by flow cytometry.
Option D: Measure action potential in purified CMs
i. Transfer the MB positive cells onto 0.1% fibronectin-coated glass bottom 
microwell dishes and culture them for 7 days.
ii. Mount the 35-mm dishes on an inverted microscope and heat the stage to 37°C 
with a heating/cooling bath temperature controller. Perfuse the cells with Tyrode’s 
solution.
iii. Record intracellular membrane potential using the EPC 7 amplifier in current 
clamp mode at 37 ± 0.5°C.
iv. Impale individual cells with the sharp microelectrodes and record the action 
potential signals.
v. Analyze action potentials using the Origin 6.0 software.
TROUBLESHOOTING
Troubleshooting advice can be found in Table 1.
TIMING
Steps 1–12: 10 days
Steps 13–15: 2 hours
Wile et al. Page 19
Nat Protoc. Author manuscript; available in PMC 2015 February 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Steps 16–22: 1 day
Steps 23–27: 1 day
Steps 28–34: 2–3 weeks
Steps 35–42: 6 hours
Step 43: 2–7 days
ANTICIPATED RESULTS
We have used the protocol described herein to enrich and isolate homogeneous populations 
of target cells from PSC differentiation culture with high throughout and high (>95%) 
purity21. Well-designed MBs targeting mRNAs specific for the cell type of interest should 
show high signal-to-background ratio (Figure 4A), whereas an MB targeting a poorly 
selected sequence could result in high non-specific signal (Figure 4A). It is also necessary to 
perform cellular tests of multiple MBs with positive control cells, even for well designed 
MBs, to ensure that at least one MB gives high fluorescence signal level, since not all MBs 
are able to access the target mRNA sequence (Figure 4B). For example, in our published 
studies21, we delivered four MBs into positive control cells (HL-1 CM), and found that two 
MBs designed to target the MYH6/7 mRNA displayed high fluorescence signal, whereas two 
MBs targeting the TNNT2 mRNA showed relatively low signal. We therefore selected the 
MHC1 MB that gave the highest signal level for subsequent CM isolation studies. Optimally 
designed MBs will give high fluorescence signal in positive control cells (Figure 4B) and 
very low signal in all other cell types, for example smooth muscle cells and cardiac 
fibroblast cells chosen to represent cells that may be present in differentiating PSCs for CM 
isolation (Figure 4C). It may also be necessary to use negative control MBs to confirm the 
signal specificity in positive control cells as shown in Figures 3B, 3C. As shown in Figure 
4D, when MHC-1 MBs were delivered into cells in the differentiating culture of mouse 
ESCs, a large amount of cells showed a high level of MB signal, and FACS sorting isolated 
49.2% cells as mouse CMs. Since PSC-derived cells may express high, medium, or low 
levels of the target gene, the FACS results may be less clear-cut than that in the positive 
control cells, as reflected by the lack of distinct populations in the FACS results shown in 
Figure 4D. However, the percentage of FACS-isolated cells based on MB signal should 
correlate well with differentiation efficiency, i.e., the expected proportion of target cells in 
the differentiating culture. This can be used to fine-tune the FACS protocol and obtain an 
initial confirmation of appropriate MB function.
After isolating MB-positive cells from the mixed cell population using FACS, it is necessary 
to confirm the characteristics of the target cells using qRT-PCR, Immunocytochemistry, 
action potential measurements, or other functional assays. It is expected that the expression 
of cell-specific genes (e.g., TNNT2 and MYH6/7 for CMs) increase in MB-positive cells 
compared with that of the mixed cell population (Figure 4E). The expression of gene 
markers from alternative lineages (e.g., Acta2 and Sox17) should show the reverse trend 
(Figure 4E). Further, it is anticipated that the vast majority (>98%) of the MB-sorted cells 
are positive for the specific protein marker, as is the case for MB-sorted CMs that highly 
expressed the cardiac marker Actn2, as revealed by immunocytochemistry (Figure 4F).
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Summary
Molecular beacons are dual-labeled oligonucleotides that fluoresce in the presence of 
complementary mRNA. This protocol describes how to use them to purify specific cell 
populations by targeting mRNAs highly expressed only in the desired cell type.
Wile et al. Page 23
Nat Protoc. Author manuscript; available in PMC 2015 February 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Molecular beacon structure and control molecular beacons
(a) A schematic of a molecular beacon in a stem-loop hairpin conformation. The stem brings 
the 5′ dye and 3′ quencher together to quench the fluorescence signal. The loop region with 
15–30 base pairs is complementary to the target sequence of specific mRNA thus providing 
specificity. (b) A schematic depicting a molecular beacon in an open conformation after 
hybridizing to its complementary target mRNA sequence. Hybridization induces a 
conformational change that separates the fluorophore from the quencher, resulting in a >10-
fold increase in fluorescence signal. (c) A schematic of a positive control molecular beacon 
with a fluorescent dye attached to both the 5′ and 3′ ends, thus is constitutively fluorescent. 
This probe is used to determine if MBs can be delivered into different cell types efficiently 
and uniformly. (d) A schematic depicting a specific negative control beacon. The four 
mutated bases should prohibit hybridization of the probe to the target region of specific 
mRNA. When delivered into 3T3 cells as negative control cells, this control beacon should 
yield very low background signal, confirming the MB specificity. (d) A predicted secondary 
structure of a cardiac specific gene, with a single stranded region highlighted and expanded.
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Figure 2. Major elements of procedure
(a) The target gene(s) abundantly expressed in a cell type of interest are identified and 
confirmed using RT-PCR in Steps 1–5. (b) MBs are designed by identifying unique target 
sequences that are accessible, and choosing a stem region and an appropriate dye-quencher 
pair. (c) MBs are tested in solution to check the quality of MB synthesis and in positive/
negative control cells to ensure that a high fluoresce signal is generated only in the specific 
cell type of interest. (d) Stem cells are differentiated into target cells (e.g., CMs), MBs are 
delivered into cells in the entire culture of mixed cell population, and MB positive cells are 
isolated using FACS. (e) MB-positive cells are characterized to confirm that they are the 
right cell type with high purity using RT-PCR, immunocytochemistry, and 
electrophysiology (for CM).
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Figure 3. Example of control experiments required to demonstrate beacon specificity
(a)Representative data using a delivery control MB in mouse ESCs (a schematic depicting a 
delivery control beacon is shown on the right). The random sequence (red nucleotides) 
delivery beacon with two dyes is used to demonstrate high delivery efficiency and 
uniformity. All dot plots depict a representative flow cytometry assay where 20,000 events 
were collected using log scales for both fluorescence and FSC measurements. Each 
condition was repeated three times to generate the SD shown. (b) Representative flow 
cytometry data using a negative control MB in mouse HL-1 cells (A schematic depicting a 
negative control beacon is shown on the right). Random negative control beacons are 
delivered into target cells to demonstrate that beacon signals do not arise from MB 
degradation or non-specific intracellular interactions. (c) Representative flow cytometry data 
using a mutant beacon as a negative control delivered into HL-1 cells to confirm MB signal 
specificity. A schematic depicting the specific negative control MB with four mutated base 
pairs in red is shown on the right. (d) Representative flow cytometry data generated using a 
MB targeting the Myh6 mRNA delivered into negative control mouse ESCs to demonstrate 
MB specificity. When the MBs are delivered into control cells a low fluorescence signal is 
generated, demonstrating MB specificity in a cellular environment. A schematic depicting a 
MB designed to hybridize to a specific target sequence (green nucleotides) is shown.
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Figure 4. Anticipated results of MB validation, optimization and target cell type characterization
(a) Examples of MB validation by fluorescence measurement in solution where MHC1 
beacon displays a normal response to target and mismatch oligonucleotides, and the 
GAPDH beacon shows a lack of specificity due to high signal level in the presence of 
mismatched oligonucleotide target. Roughly 10% of MB designs fail to adequately 
discriminate between target and mismatched oligonucleotides. (b) Delivery of MBs into 
positive control cells (e.g., HL-1 CM) resulted in different signal levels. For CM isolation, 
two MBs targeting the MYH6/7 mRNA displayed high fluorescence signal whereas two 
MBs targeting the TNNT2 mRNA showed relatively low signal. MB design MHC1 gave the 
highest signal level, therefore should be selected for subsequent use. Roughly 50–80% of 
MBs fail to adequately discriminate between positive and negative control cells. Data in this 
histogram represent percentage of MB positive cells based on flow cytometry, error bars 
represent one SD. (c) The MHC-1 MB was subsequently tested in non-cardiac cell types 
including cultured smooth muscle cells and cardiac fibroblasts that may be present in a 
differentiating culture of PSCs. A very low percentage of these cells had high fluorescence 
intensity, which is expected based on the results shown in Figure 3. All dot plots depict a 
representative flow cytometry assay where 20,000 events were collected using log scales for 
both fluorescence and FSC measurements. Each condition was repeated three times to 
generate the SD shown. (d) The MHC-1 MB was tested in cells derived from mouse ESCs. 
A high percentage of these cells showed a significantly increased beacon signal, which 
correlated well with the proportion of TNNT2 positive cells. However, PSC-derived cells 
may express high, medium, or low levels of the target gene, and the results from FACS 
assays are likely to be less clear-cut than those seen in the control cells. (e) Results of qRT-
PCR of the mixed cell population (PRE) from differentiating mouse ESCs and MB positive 
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cells (POST) after MB based sorting displaying increased expression of CM-specific genes 
(Tnnt2 and Myh7) and decreased expression of gene markers (Acta2 and Sox17) from 
alternative lineages. Roughly 75% of MBs validated in previous steps are useful for sorting 
stem cell derived CMs. Data in these histogram represent comparative RT-PCR with all 
genes normalized to GAPDH via the ddCT method described in Step 5, error bars represent 
one SD, t-Tests were carried out to determine significance. (f) Immunocytochemistry results 
showing >98% of the MB-sorted cells from differentiating mouse ESCs are positive for 
cardiac marker Actn2. The lower image is an enlargement of the upper image. Scale bars, 20 
μm.
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Table 1
Troubleshooting
Step Problem Possible Reason Solutions
7, 8, 13 MB does not fluoresce in the 
presence of the target 
oligonucleotide
The MB stem-loop structure is too stable
The MB loop sequence is too short or too 
AT rich
The stem should be weakened by decreasing its 
length and/or GC content
The loop length and/or GC content of the MB 
should be increased
8, 13 MB fluoresces in the 
presence of a mismatch 
oligonucleotide
The hybridization of the MB with the 
mismatch oligonucleotide is more 
energetically favorable than the formation 
of the stem-loop MB structure despite the 
energy penalties of the mismatches
The stem should be strengthened by increase its 
GC content and/or length
11 MB fluorescence cannot be 
detected in GFP+ cells
The GFP fluorescence is detectable at other 
wavelengths, and it is obscuring beacon 
signals because of its intensity
Instead of Cy3 or FAM dyes, switch to a dye with 
an even more spectrally distinct emission 
wavelength such as Cy5
Ensure that your analysis method is using an 
appropriate excitation laser that avoids exciting 
GFP and maximizes the light absorbed by the MB 
dye
15 MB fluorescence cannot 
initially be detected in 
positive wells
The MBs have not bound to their targets in 
the solution
Allow more time for the beacon and target 
solutions to mix, or mix the solutions using a shake 
function on the microplate reader, or mix the 
solutions more vigorously while pipetting
21 Fewer than 80% of the cells 
are positive for delivery MB 
signal
Cell membranes are not porous enough for 
a long enough period of time for MBs to 
enter the cell
Continue to test other electroporation parameters to 
increase the transfection efficiency. If transfection 
cannot be improved, switch to a more easily 
manipulated cell type
26 The negative control cells are 
generating a false positive 
signal with MB targeted 
towards the gene of interest
The control cells actually do express the 
gene of interest (verify by RT-PCR)
The gene is not expressed but a non-
specific interaction in the control cells is 
causing MB to fluoresce (verify by RT-
PCR)
The gene is not expressed but a non-
specific interaction in the control cells is 
causing MB to fluoresce in the cytoplasm 
(verify by RT-PCR and microscopy)
Use a different cell type as a control
Check the cells using a microscope to observe 
subcellular localization. If MBs are apparent in the 
nucleus, try reducing the time between 
electroporation and analysis
Change the mRNA target region to avoid non-
specific interactions. This will require the 
development of a new MB
26 The positive control cells do 
not give a strong MB signal
The MB targeting sequence may be 
inaccessible
Redesign MB to target a different region of the 
gene to have better accessibility
39 Fewer than 80% of the 
differentiated cells are 
positive for delivery MB 
signal
Cell membranes are not porous enough for 
a long enough period of time for MBs to 
enter the cell
Continue to test other electroporation parameters to 
increase the transfection efficiency. If transfection 
cannot be improved, normalize all values to the 
transfection percentage. Since the dyes on the 
delivery control and cell- specific beacon are 
spectrally distinct they may be delivered 
concurrently for easier analysis.
41 The positive control cells do 
not give a strong cell specific 
MB signal
The MB targeting sequence may be 
inaccessible
Redesign MB to target a different region of the 
gene to have better accessibility
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Table 2
Validated molecular beacon designs
Target Gene Species Sequence
Myosin Heavy Chain (cardiac) Mouse, Human CCTCCATCTTCTTCTTCACGGAGG
Iroquois Homeobox 4 Mouse CAGGCAGAGAGTAGAAAGCAGATGCCTG
Oct4 Mouse CGCAGTCCAGGTTCTCTTGTCTCTGCG
Random No Reactivity ACGACGCGACAAGCGCACCGATACGTCGT
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